Question special

Dr. Kesselheim touched on this in a JAMA paper, with a few options (educate docs/patients on cost of meds, although they might not care since they aren't paying for it; push Congress to allow for negotiation, but seems politically unfeasible given pharma lobby; push the US Trademark and Patents office to become more stringent in granting extensions, but unsure if this is likely to work). Any further thoughts would be much appreciated.